Neuroendocrine Tumors Treatment Market Estimated to Obtain Significant Growth in Forecast Period (2019 - 2026)

‘Global Neuroendocrine Tumors Treatment Market - Size, Share and Forecast (2019-2026)’ from DataM Intelligence provides expert analysis into the market share, size, industry outlook, volume, major manufacturers and future trends in this industry. Probable impediments have also been discussed so as to allow the user in getting a better understanding of the key market drivers and restraints.

According to Novartis, each year, 5.25 out of every 100,000 people in the US are diagnosed with NETs.

Global Neuroendocrine Tumors Treatment Market Dynamics
Neuroendocrine Tumor Research Foundation (NETRF) received eight new grants totaling $2.5 million for research on neuroendocrine cancer. With this newest round of funding, NETRF is going to expand its portfolio to include research into lung neuroendocrine tumors. Similarly, the Neuroendocrine Tumour Research Foundation (NETRF), invested around $1.5 million for the development of advanced radiation therapy – Peptide Receptor Radionuclide Therapy (PRRT).
Lack of skilled healthcare professionals and lower adoption of advanced treatment technologies
are going to restrain the market in the forecast period.

Request for the free sample of the report - https://www.datamintelligence.com/research-report/neuroendocrine-tumors-treatment-market

Global Neuroendocrine Tumors Treatment Market Segment Analysis
The global neuroendocrine tumors treatment market can be segmented by treatment type as Surgery, drug therapy, Interventional Radiology and Nuclear Medicines. Drug therapies are further segmented as Somatostatin Analogs, Targeted Therapy and Immunotherapy, Chemotherapy and Nuclear Medicine, Interventional Radiology is further segmented as Hepatic Embolization and Radiofrequency Ablation. By treatment site market can be segmented into Gastrointestinal, Pancreas, Lung, and Others.
The gastrointestinal segment is expected to account for the largest market over the period of the forecast as the gastrointestinal tract is more prone to NETs. According to the statistics published by Novartis in 2015, around 61% of the total NETs are in the gastrointestinal tract. Moreover, according to the American Society of Clinical Oncology (ASCO), in 2018, around 10,000 adults in the U.S. were diagnosed with gastrointestinal NETs.

Global Neuroendocrine Tumors Treatment Market Regional Analysis
Geographically, the global neuroendocrine tumors treatment market is divided into North America, Europe, South America, Asia-Pacific and the Middle East and Africa.
Technological advancement in targeted therapy and enhanced funding in the research and development sector is helping boost the North America neuroendocrine tumors treatment market. As per Cancer.Net, it is estimated that more than 12,000 people in the US are diagnosed with a NET each year, and approximately 170,000 people are living with one. The number of people diagnosed with this type of tumor is increasing by more than 5% each year. Patients undergoing NETs treatment in the US are supported by insurance policies such as Medicaid, Tricare, and Medicare. Many of the major companies in this segment have headquarters in the US and thus consider North America as their primary market for product launch and investment.

Global Neuroendocrine Tumors Treatment Market Company Trends
Some of the major key players in the market are Pfizer, Inc., Novartis AG, Ipsen Pharma, Dauntless Pharmaceuticals, Inc., Exelixis, Inc., Hutchinson Medipharma Limited, Progenics Pharmaceuticals, Inc., Tarveda Therapeutics and Boehringer Ingelheim International GmbH. Novartis AG has the highest number of clinical trials followed by Pfizer Inc. and Ipsen Pharma.
In June 2018, Boehringer Ingelheim laid the foundation stone for Boehringer Ingelheim Biologicals Development Centre in Biberach, Germany. The company is making an estimated investment of $266.4 million. The centre will specialize in immune-oncology and immunology.
In January 2018, Novartis AG announced to purchase all the ordinary shares from its subsidiary group Novartis Groupe France S.A., which includes Advanced Accelerator Applications S.A.

Read more information about the research report - https://www.datamintelligence.com/research-report/neuroendocrine-tumors-treatment-market

This report contains the table of contents -
1. Global Neuroendocrine Tumors Treatment Market Methodology and Scope
2. Global Neuroendocrine Tumors Treatment Market – Market Definition and Overview
3.Global Neuroendocrine Tumors Treatment Market – Executive Summary
4.Global Neuroendocrine Tumors Treatment Market – Market Dynamics
5.Global Neuroendocrine Tumors Treatment Market – Industry Analysis
6.Global Neuroendocrine Tumors Treatment Market – Pipeline Analysis
7.Global Neuroendocrine Tumors Treatment Market – By Treatment Type
8.Global Neuroendocrine Tumors Treatment Market – By Treatment Site
9.Global Neuroendocrine Tumors Treatment Market – By Region
10. Global Market – Competitive Landscape
11. Company Profiles
12. Global Neuroendocrine Tumors Treatment Market – Premium Insights
13. Global Neuroendocrine Tumors Treatment Market – DataM

Corporate Address
1st floor, Phoenix Tech Tower, Plot no: 14/46, Habsidguda, IDA-Uppal, Hyderabad-500039, Telangana

Email
info@datamintelligence.com

Phone
+1 877-441-4866

About DataM Intelligence

DataM Intelligence 4Market Research is a Market Intelligence and Business Research firm, based in India. It aims to bridge the two main aspects of a business decision - opinion and supportive data.

DMI is currently strengthening its cross-industrial database for sectors including Chemicals, Materials, Agriculture, Healthcare Services, Animal Nutrition, Consumer Goods, Food & Beverages, Industrial Machinery and Automation among others.

This release was published on openPR.